Provided by Tiger Fintech (Singapore) Pte. Ltd.

SELLAS Life Sciences Group Inc.

2.00
+0.09004.71%
Post-market: 2.060.0600+3.00%19:59 EDT
Volume:5.60M
Turnover:11.41M
Market Cap:250.00M
PE:-6.26
High:2.15
Open:1.99
Low:1.94
Close:1.91
52wk High:2.27
52wk Low:0.7720
Shares:125.00M
Float Shares:103.53M
Volume Ratio:2.63
T/O Rate:5.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3195
EPS(LYR):-0.5046
ROE:-180.71%
ROA:-68.75%
PB:9.56
PE(LYR):-3.96

Loading ...

SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025

GlobeNewswire
·
Yesterday

Sellas Life Sciences files to sell 19.69M shares of common stock for holders

TIPRANKS
·
Oct 11

Sellas Life Sciences Group Inc: Files for Resale by Selling Stockholders of up to an Aggregate of 19.7 Mln Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Oct 11

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Simply Wall St.
·
Oct 08

Sellas Life Sciences Group Extends Times Square Tower Sublease Through September 2027

Reuters
·
Oct 04

SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update

GlobeNewswire
·
Sep 30

Sellas Life Sciences to Receive $23.6 Million From Exercise of Warrants

MT Newswires Live
·
Sep 11

BRIEF-Sellas Life Sciences Secures $23.6 Million in Gross Proceeds Through Institutional Warrant Exercise

Reuters
·
Sep 11

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds

GlobeNewswire
·
Sep 11

Fury Announces Results of Preliminary Economic Assessment for the Eau Claire Gold Deposit with a Base Case After-Tax NPV (5%) of $554M and After-Tax IRR of 41%

GlobeNewswire
·
Sep 02

SELLAS Life Sciences Gr Q2 EPS $(0.07) Beats $(0.08) Estimate

Benzinga
·
Aug 13

Sellas Life Sciences Group Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 13

BRIEF-SELLAS Life Sciences Q2 Net Income USD -6.601 Million

Reuters
·
Aug 13

Sellas Life Sciences Q2 Basic EPS USD -0.07

THOMSON REUTERS
·
Aug 13

Sellas Life Sciences Q2 Operating Expenses USD 6.873 Million

THOMSON REUTERS
·
Aug 13

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 13

Sellas Life Sciences Group Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
Aug 09

BRIEF-Sellas Gets Green Light to Continue Phase 3 REGAL Trial of GPS in AML After Positive Data Review

Reuters
·
Aug 07

Sellas Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 Regal Trial of Gps in Aml Without Modification

THOMSON REUTERS
·
Aug 07

Sellas Life Sciences Group Inc: Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events

THOMSON REUTERS
·
Aug 07